2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management
Year: 2026
Type: review
Abstract: Hormone receptor-positive metastatic breast cancer remains a major clinical burden and is characterized by sequential endocrine resistance over the disease course. In 2023, the Taiwan Breast Cancer Society (TBCS) published an expert consensus to support real-world decision-making in Taiwan. Subsequently, rapid advances in biomarker-informed strategies (e.g., estrogen receptor 1 and PI3K/AKT pathway alterations), endocrine partners, estrogen receptor (ER)-targeting agents (including oral selective ER degraders and emerging protein degraders), and the expanding role of antibody-drug conjugates based on human epidermal growth factor receptor 2 expression categories have materially increased the complexity of treatment selection and sequencing. Therefore, TBCS convened an expert panel to update the previous consensus while preserving its foundational framework and eight-chapter structure: risk evaluation and biomarker testing (I/II), first-line treatment selection (I/II), second-line treatment selection (I/II), and treatment options other than endocrine-based approaches (I/II). A multidisciplinary panel conducted a systematic literature review and iterative discussions using a modified Delphi process to identify the key clinical questions, update and refine statements where new evidence was practice-changing, and maintain continuity with the 2023 Consensus. The panel formulated updated recommendations, assigned levels of evidence and strengths of recommendations, and the key updates were integrated into practical treatment algorithms reflecting Taiwan's practice considerations. This updated consensus provides a continuity-based, yet evidence-responsive framework to facilitate the integration of emerging therapies into clinical practice in Taiwan and the Asia-Pacific region.
Source: Journal of Breast Cancer
Authors: Jiun-I Lai, Chih-Chiang Hung, Chin-Yao Lin, Chung-Liang Li, Wei-Pang Chung, Ching-Hung Lin, Cheng-Ping Yu, Ming-Yang Wang, Sung-Chao Chu, Chen-Teng Wu, Kuo-Ting Lee, Shyr-Ming Sheen-Chen, Jyh-Cherng Yu, Zhi-Jie Hong, Chao-Ming Hung, Chin-Sheng Hung, King-Jen Chang, Chen-Hsiang Chang, Yuan-Ching Chang, Hsien-Kun Chang, Dwan-Ying Chang, Yao-Jen Chang, Wen-Hung Kuo, Wen-Ling Kuo, Shou-Tung Chen, I-Chun Chen, Fang-Ming Chen, Shin-Cheh Chen, Wei-Wu Chen, Dar-Ren Chen, Ling-Ming Tseng, Yen-Dun Tzeng, Chi-Cheng Huang, Chiun-Sheng Huang, Hsien-Tang Yeh, Guo-Shiou Liao, Ta-Chung Chao, Tsu-Yi Chao, Liang-Chih Liu, Chun-Yu Liu, Ching-Hua Tsai, Fiona Tsui-Fen Cheng, Yen-Shen Lu, Ming-Shen Dai, Chi-Feng Chung, Kun-Ming Rau
Institutions: National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Taipei Medical University Hospital, E-Da Hospital, Taichung Veterans General Hospital, Taipei Medical University, I-Shou University, National Taiwan University, National Taiwan University Hospital, Kaohsiung Medical University, Kaohsiung Medical University Chung-Ho Memorial Hospital, National Cheng Kung University Hospital, National Cheng Kung University, Tri-Service General Hospital, National Defense Medical Center, Tzu Chi University, Hualien Tzu Chi Medical Center, China Medical University Hospital, Mackay Memorial Hospital, Taipei Tzu Chi Hospital, Chang Gung Memorial Hospital, Taoyuan Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital, Chang Gung University, Changhua Christian Hospital, Kaohsiung Veterans General Hospital, Luodong Poh-Ai Hospital, Taipei Medical University-Shuang Ho Hospital, China Medical University, Kaohsiung Chang Gung Memorial Hospital, Shin Kong WHS Memorial Hospital, Koo Foundation Sun Yat-Sen Cancer Center, Yuan's General Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $500
OpenAlex ID: W7166459751